CN110313599A - 一种降尿酸果冻及其制备方法 - Google Patents
一种降尿酸果冻及其制备方法 Download PDFInfo
- Publication number
- CN110313599A CN110313599A CN201810277864.6A CN201810277864A CN110313599A CN 110313599 A CN110313599 A CN 110313599A CN 201810277864 A CN201810277864 A CN 201810277864A CN 110313599 A CN110313599 A CN 110313599A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- jelly
- trioxypurine
- enterococcus faecalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015110 jellies Nutrition 0.000 title claims abstract description 21
- 239000008274 jelly Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 52
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 12
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- 235000003283 Pachira macrocarpa Nutrition 0.000 claims abstract description 10
- 235000014364 Trapa natans Nutrition 0.000 claims abstract description 10
- 235000009165 saligot Nutrition 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 239000000654 additive Substances 0.000 claims abstract 3
- 230000000996 additive effect Effects 0.000 claims abstract 3
- 240000006432 Carica papaya Species 0.000 claims abstract 2
- 239000002994 raw material Substances 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 241000194032 Enterococcus faecalis Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 241001083492 Trapa Species 0.000 claims description 9
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 241000219173 Carica Species 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims 2
- 241000186012 Bifidobacterium breve Species 0.000 claims 2
- 241001608472 Bifidobacterium longum Species 0.000 claims 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 229940004120 bifidobacterium infantis Drugs 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 24
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 21
- 229940116269 uric acid Drugs 0.000 abstract description 21
- 201000005569 Gout Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 4
- 240000001085 Trapa natans Species 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 201000001431 Hyperuricemia Diseases 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241001092040 Crataegus Species 0.000 description 6
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010092464 Urate Oxidase Proteins 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical class ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- SFCXYSXJRRDDNZ-UHFFFAOYSA-N [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 Chemical compound [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 SFCXYSXJRRDDNZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
- A23L21/15—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products derived from fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种降尿酸果冻及其制备方法,其原料按重量比包括:葛根粉:25‑40份,淡竹叶粉:20‑30份,茯苓粉:15‑20份,木瓜粉:13‑20份,薏苡仁:22‑30份,山楂:15‑25份,枸杞:5‑10份,荸荠:5‑10份,益生菌冻干粉的添加量是1×107cfu/g‑1×108cfu/g。本发明对尿酸高引起的痛风、风湿性关节炎等有较好的疗效,能显著降低体内尿酸含量,缓解痛风症状,适于痛风患者。
Description
技术领域
本发明涉及一种食品,尤其涉及一种降尿酸果冻及其制备方法。
背景技术
痛风( gout )是长期嘌呤代谢障碍、血尿酸增高引起的代谢性疾病,是一种古老的疾病,在欧洲和北美较为多见。高尿酸血症( hyperuricemia, HUM)是痛风的重要生化基础,但痛风的患病率远低于高尿酸血症。过去这种病在亚洲或东方人中比较少见,但自20世纪50年代以后,日本、中国台湾等地区经济迅速发展,痛风及高尿酸血症患病逐渐增加。我国在20世纪80年代后的患病情况也有上升趋势。
因种族和地区不同而有差异,有关痛风的发病率报道并不多。欧美地区痛风的发病人数约占总人口的0.13% ~ 0.37% ,年发病率为0.20‰~0.35‰。1991年 JohnesHopkins研究发现30岁以上的男性累积发病率达9‰;最近有人对2064名男性研究发现其发病率为2.8‰。
随着经济的发展,亚洲地区近二十年高尿酸血症患病率有明显上升趋势。在20世纪80年代初进行人群调查时得出,血尿酸平均水平男性为( 4.4±1.0) mg /100 ml,女性为( 3.4±0.9) mg/100 ml。高尿酸血症患病率男性为4% ,女性为3% 。20世纪90年代后期山东的人群调查血尿酸男性平均为( 289.6± 76.6)μmol /L,女性为( 236.5±63.3)μmol/L。高尿酸血症患病率男性为5.79% ,女性为2.44% ,痛风患病率0.0352%。同期上海调查高尿酸血症患病率为10.1% (男性14.2% , 女性7.1% ) ,共发现7例男性痛风。
人类治疗痛风的历史悠久,但疗法一直没有根本的改变。目前所使用的降尿酸的药物主要包括三大类即促进尿酸排泄和抑制尿酸合成药物及尿酸酶。但这些药物耐受性低、副作用多,且有一定依赖性,通常表现为服药后症状迅速缓解,停药后病情马上复发,不适宜长期服用。尿酸酶作为能直接分解尿酸的药物为目前的研究热点,国内外已有多种来源的尿酸酶基因得到克隆表达并商品化。如拉布立酶及聚乙二醇重组尿酸酶均为新一代促尿酸分解药物,能明显降低体内尿酸水平,但属于生物制剂,易产生过敏反应且价格昂贵等,未在临床广泛应用。因此寻找高效、低毒的降尿酸药物是今后降尿酸药物研发的新方向。
肠道微生物群在胃肠道执行许多功能,包括调节黏膜的正常发育,协助成熟的免疫组织进而促进免疫耐受,清除抗原或潜在的致病菌,控制养分吸收和代谢,防止病原微生物的传播等。其以人体的营养成分维持生存和代谢,与人体共同对外界的环境因素做出反应并进行代谢和免疫活性来维持人体健康,并随饮食及肠道内环境的改变而发生适应性改变,与人类疾病的关系日益密切。
高尿酸血症与肠道菌群的关系目前相关研究处于起步阶段。Vitetta与Gobe研究认为益生菌具有分解尿毒症毒素作用,慢性肾脏疾病起源于胃肠道,肠道微生物群和微生。生物代谢组在尿毒症保留溶质的扩散中扮演重要角色,能显著降低尿酸氮及肌酐、尿酸水平。
高尿酸血症患者存在菌群失调现象,表现为乳酸杆菌及双歧杆菌、粪肠球菌数量减少,而总需氧菌及大肠杆菌、拟杆菌数量增加。说明高尿酸血症可能与菌群失调,乳酸杆菌、双歧杆菌等有益菌减少有关。有研究表明随着乳酸杆菌及双歧杆菌数量减少,菌群尿酸处理能力下降,表明乳酸杆菌及双歧杆菌均具有降尿酸作用。综上所述,肠道菌群失调可能是促进高尿酸血症发生的原因之一。
乳酸菌(Lactic acid bacteria,LAB)是指一群可发酵糖类并产生大量乳酸的革兰氏阳性球菌或杆菌的统称。它们是人类肠道重要的生理菌群,对机体有多种其他正常生理菌群无法比拟的生理作用14J,因而受到国内外研究者的广泛关注。
作为人体肠道内的正常菌群一员,乳酸菌在高尿酸血症治疗方向上拥有药物治疗无可比拟的优点:①无药物不良反应②几乎不需要限制饮食,患者依从度高。日本大琢制药株式会社已经发现某些乳酸菌具有降低血尿酸的能力,并在动物实验中证实了乳酸菌降低血尿酸效果的有效性,这些乳酸菌现已被申请专利。
自从法国巴斯德研究院蒂塞尔(Tissier)等于1899年在母乳喂养的婴儿粪便中发现双歧杆菌。经过近一个世纪人们不懈的研究,现已认识到该菌是人体重要的益生菌,是人体肠道内数量占优势的一种菌,终生存在于人体并与人体健康息息相关。
双歧杆菌作为肠道内优势菌,能抑制致病菌的入侵、繁殖,人体内的吲哚酚、氨和尸胺等有毒物质也明显减少;同时双歧杆菌还能利用这些物质作为营养源,减少肠道内毒素、尿素酶的含量,使血液中内毒素和氨含量下降。
粪肠球菌(Enterococcus faecalis)是革兰氏阳性,过氧化氢阴性球菌,是人和动物肠道内主要菌群之一,其能产生天然抗生素,有利于机体健康;同时还能产生细菌素等抑菌物质,抑制大肠杆菌和沙门氏菌等病原菌的生长,改善肠道微环境;还能抑制肠道内产尿素酶细菌和腐败菌的繁殖,减少肠道尿素酶和内毒素的含量,使血液中氨和内毒素的含量下降。粪肠球菌(E. faecalis)作为一种益生菌,在医学和食品工程领域得到广泛应用。
葛根,为豆科植物野葛或甘葛藤的块根,属药食两用植物,既富含淀粉、膳食纤维、氨基酸、维生素、矿物质等营养物质,还含有异黄酮类、葛根甙类、三萜皂甙类、生物碱等活性成分,具有明显的抗肿瘤、清除自由基、治疗心血管疾病、调节血脂代谢、改善胰岛功能等功效,广泛应用于食品、药品、保健品等行业。
葛根粉是将葛根切片,经水磨而澄取的淀粉。具有改善微循环,溶解并防止尿酸盐结晶沉积。营养心肌,解肌发表,降糖降脂,升举阳气,止渴止泻等功效。
淡竹叶为禾本科,淡竹叶属多年生草本植物,根状茎。须根中部可膨大为纺缍形肉质块根,黄白色。叶披针形,圆锥花序;颖果椭圆形。生于山坡林下阴湿处。
其性味甘淡,能清心、利尿、祛烦躁,对于牙龈肿痛、口腔炎等有良好的疗效,民间多用其茎叶制作夏日消暑的凉茶饮用。根药用,具有清热除烦,利尿通淋的功效十主治热病烦渴,口舌生疮,牙龈肿痛,小儿惊啼,肺热咳嗽,胃热呕哕,小便赤涩淋浊。
茯苓是利水渗湿药中的常用药。主要含多聚糖类、β茯苓聚糖、羧甲基茯苓多糖、茯苓多糖、茯苓素、茯苓酸、三萜类类、卵磷脂、蛋白质及多种微量元素等成分。功效利水渗湿、健脾和胃、宁心安神。
茯苓素是利尿消肿的主要成分。茯苓素能激活细胞膜上 Na+、 K+、 ATP 酶 , 而ATP 酶与利尿有关。实验证明茯苓素不仅能结合到肾细胞醛固酮受体上,提离尿中钠与钾比值,且具有剂量依赖关系。对水肿患者,有利于尿液的排出,恢复肾功能、消除蛋白尿。常用于小便不利、四肢水肿、痰饮等症。
发明内容
本发明涉及一种有助降低人体中尿酸含量的果冻,对缓解痛风人群的症状具有积极的作用。
所述的粪肠球菌保藏于中国典型培养物保藏中心武汉大学保藏中心,保藏号为CCTCCNO M 2018012,保藏地址为湖北省武汉市武昌珞珈山,保藏日期为2018年1月8日,命名为粪肠球菌Enterococcus s faecalis EF23粪肠球菌EF23。
具体实施例
为了更好地阐述本发明内容,下面用若干较佳的具体实施例进行说明。但这些具体实施例只是为了说明本发明的内容,而不是对本发明内容进行限制。
(1)样品的制备:降尿酸果冻按下述配方进行配备
样品1:葛根粉:25份,淡竹叶粉20份,茯苓粉15份,木瓜粉13份,薏苡仁22份,山楂15份,枸杞5份,荸荠5份;称取的葛根粉、淡竹叶粉、茯苓粉、木瓜粉烘干,混匀,加入6倍的水,混匀;称取的薏苡仁、山楂、枸杞、荸荠,加 10 倍量水,加热提取 2 次,每次 2 小时,滤过,合并滤液,滤液浓缩至相对密度为 1.18-1.22(60℃)的清膏;
取混合物5-30%及清膏5-30%,木糖醇 5-15%,果冻粉 0.4-2.0%混匀后加入益生菌冻干粉,水加至 100% , 充分混合均匀,煮沸后灭菌,灌封果冻。
样品2:葛根粉40份,淡竹叶粉30份,茯苓粉20份,木瓜粉20份,薏苡仁30份,山楂25份,枸杞10份,荸荠10份;称取的葛根粉、淡竹叶粉、茯苓粉、木瓜粉烘干,混匀,加入6倍的水,混匀;称取的薏苡仁、山楂、枸杞、荸荠,加 10 倍量水,加热提取 2 次,每次 2 小时,滤过,合并滤液,滤液浓缩至相对密度为 1.18-1.22(60℃)的清膏;
取混合物5-30%及清膏5-30%,木糖醇 5-15%,果冻粉 0.4-2.0%混匀后加入益生菌冻干粉,水加至 100% , 充分混合均匀,煮沸后灭菌,灌封果冻。
样品3:葛根粉:32份,淡竹叶粉25份,茯苓粉:17份,木瓜粉16份,薏苡仁26份,山楂20份,枸杞7份,荸荠7份;称取的葛根粉、淡竹叶粉、茯苓粉、木瓜粉烘干,混匀,加入6倍的水,混匀;称取的薏苡仁、山楂、枸杞、荸荠,加 10 倍量水,加热提取 2 次,每次 2 小时,滤过,合并滤液,滤液浓缩至相对密度为 1.18-1.22(60℃)的清膏;
取混合物5-30%及清膏5-30%,木糖醇 5-15%,果冻粉 0.4-2.0%混匀后加入益生菌冻干粉,水加至 100% , 充分混合均匀,煮沸后灭菌,灌封果冻。
(2)高尿酸血症小鼠模型的制备
动物:昆明种小鼠60只, 体重20g±2 g ,雌雄各半。
分组:小鼠分为空白组、模型组。
药物:黄嘌呤(Xanthine) 为Sigma 公司产品;盐酸乙胺丁醇片(Ethambutol) 为广东省河源康泰制药厂产品;
给药:模型组小鼠均灌胃600mg/kg黄嘌呤以及250mg/kg乙胺丁醇,连续给药 5天;空白组在同等条件下给予等容积蒸馏水灌胃;
眼眶取血:于第5天处死动物, 眼眶取血, 分离血清, 用Trinder 法测定血尿酸含量。实验结果如表1所示。
表 1 各造模组血尿酸与正常对照组血尿酸的比较
组别 | 动物数(n) | x±s |
空白组 | 10 | 153.11 ±36.16 |
模型组 | 40 | 220.86±48.42* |
*与正常对照组比较P <0.05
模型组与空白组比较,血尿酸值极明显升高,证明模型非常成功。
(3)将造模成功的小鼠分为4组,分别为模型组、样品1、样品2、样品3,每组10只;空白组和模型组灌胃生理盐水,试验组按 0.2g/kg浓度灌胃生理盐水,其他各组0.2g/kg浓度灌胃喂食,每日1次,连续 7天。于第7天,摘眼球取血,水浴(37℃)中静置至分层后,1800r/min离心10min,取血清测定血尿酸值,进行组间差异性比较。实验结果见表2。
表 2 有助于降低尿酸的果冻对小鼠高尿酸血症模型血尿酸的影响
组别 | 动物数(n) | 血尿酸值(U/L) |
空白组 | 10 | 153.11 ±36.16 |
模型组 | 10 | 220.86±48.42 |
样品1 | 10 | 190.65±16.35* |
样品2 | 10 | 172.65±18.34* |
样品3 | 10 | 161.51±25.72* |
*与模型组比较P <0.05
样品1、2、3组与模型组比较,血尿酸值有较明显下降,对缓解痛风人群的症状具有积极的作用。
Claims (6)
1.一种降尿酸果冻,其特征在于,其原料按重量比包括 :葛根粉:25-40份,淡竹叶粉:20-30份,茯苓粉:15-20份,木瓜粉:13-20份,薏苡仁:22-30份,山楂:15-25份,枸杞:5-10份,荸荠:5-10份,益生菌冻干粉的添加量是1×107cfu/g - 1×108cfu/g。
2.如权利要求 1 所述的一种降尿酸果冻,其特征在于,所述益生菌冻干粉中的益生菌选自肠道内双歧杆菌(Bifidobacteriuminfantis)、长双歧杆菌(Bifidobacteriumlongum)、两歧双歧杆菌(Bifidobacteriumbifidum)、青春双歧杆菌(Bifidobacteriumadolescentis)、短双歧杆菌(Bifidobacteriumbreve)、粪肠球菌Enterococcus faecalis EF23中的一种或多种;所述益生菌的添加量为1×107cfu/g ~ 1×108cfu/g。
3.如权利要求 1 所述的一种降尿酸果冻,其特征在于,所述的粪肠球菌Enterococcusfaecalis EF23是具有高表达Sir2样蛋白能力的粪肠球菌Enterococcus faecalis EF23。
4.如权利要求 1 所述的一种降尿酸果冻,其特征在于,粪肠球菌Enterococcusfaecalis EF23保藏于湖北省武汉市中国典型培养物保藏中心,保藏号为CCTCC NO:M2018012,保藏地址为湖北省武汉市武昌珞珈山,保藏日期为2018年1月25日。
5.如权利要求 1 所述的一种降尿酸果冻及其制备方法,其特征在于:所述的果冻制作方法包括如下步骤 :
(1)按照以下重量份称取组分:葛根粉:25-40份,淡竹叶粉:20-30份,茯苓粉:15-20份,木瓜粉:13-20份,薏苡仁:22-30份,山楂:15-25份,枸杞:5-10份,荸荠:5-10份;
(2)称取的葛根粉、淡竹叶粉、茯苓粉、木瓜粉烘干,混匀,加入6倍的水,混匀;
(3)称取的薏苡仁、山楂、枸杞、荸荠,加 10 倍量水,加热提取 2 次,每次 2 小时,滤过,合并滤液,滤液浓缩至相对密度为 1.18-1.22(60℃)的清膏;
(4)将步骤(2)混合物5-30%及步骤(3)清膏5-30%,木糖醇 5-15%,果冻粉 0.4-2.0%混匀后,加入益生菌冻干粉加水至 100% , 充分混合均匀,进行煮沸。
6. 如权利要求 1 所述的一种降尿酸果冻及其制备方法,其特征在于:将步骤(5)得到的混合物进行灌装、密封。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810277864.6A CN110313599A (zh) | 2018-03-30 | 2018-03-30 | 一种降尿酸果冻及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810277864.6A CN110313599A (zh) | 2018-03-30 | 2018-03-30 | 一种降尿酸果冻及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110313599A true CN110313599A (zh) | 2019-10-11 |
Family
ID=68111889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810277864.6A Pending CN110313599A (zh) | 2018-03-30 | 2018-03-30 | 一种降尿酸果冻及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110313599A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111195266A (zh) * | 2019-12-20 | 2020-05-26 | 江苏微康生物科技有限公司 | 具有缓解高尿酸作用的益生菌组合物及其应用 |
CN111248382A (zh) * | 2020-02-28 | 2020-06-09 | 山东理工大学 | 栀子茯苓复合饮品及其制备方法 |
CN115895966A (zh) * | 2022-11-30 | 2023-04-04 | 天津小薇生物科技有限公司 | 一株辅助缓解痛风的两歧双歧杆菌bl002及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009143820A (ja) * | 2007-12-12 | 2009-07-02 | Tsujido Chemical Corp | 高尿酸血症の予防または改善剤 |
CN104664369A (zh) * | 2015-01-14 | 2015-06-03 | 厦门医学高等专科学校 | 一种降血压降尿酸的明日草保健食品及其制备方法 |
CN105169096A (zh) * | 2014-08-06 | 2015-12-23 | 成都中医药大学附属医院 | 一种治疗痛风或/和高尿酸血症的药物组合物 |
CN105614860A (zh) * | 2016-01-22 | 2016-06-01 | 湖南营养树科技有限公司 | 一种益生菌复配低聚肽降尿酸营养补充剂 |
CN105876777A (zh) * | 2016-04-12 | 2016-08-24 | 周安琪 | 具有降低尿酸作用的食品及其制备工艺 |
CN106720797A (zh) * | 2016-12-29 | 2017-05-31 | 武汉万松堂健康产业有限公司 | 一种具有降尿酸、护肝强肾功效的养生茶及其制备方法 |
CN106901287A (zh) * | 2017-03-17 | 2017-06-30 | 济南大学 | 一种基于益生菌发酵的中药解酒护肝果冻及制备方法 |
CN106975028A (zh) * | 2017-02-24 | 2017-07-25 | 广西健铧健康产业有限公司 | 一种治疗痛风的中药制剂的制备方法 |
CN107136377A (zh) * | 2017-06-21 | 2017-09-08 | 武汉万松堂健康产业有限公司 | 一种针对痛风及高尿酸人群的复合固体饮料及其制备方法 |
-
2018
- 2018-03-30 CN CN201810277864.6A patent/CN110313599A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009143820A (ja) * | 2007-12-12 | 2009-07-02 | Tsujido Chemical Corp | 高尿酸血症の予防または改善剤 |
CN105169096A (zh) * | 2014-08-06 | 2015-12-23 | 成都中医药大学附属医院 | 一种治疗痛风或/和高尿酸血症的药物组合物 |
CN104664369A (zh) * | 2015-01-14 | 2015-06-03 | 厦门医学高等专科学校 | 一种降血压降尿酸的明日草保健食品及其制备方法 |
CN105614860A (zh) * | 2016-01-22 | 2016-06-01 | 湖南营养树科技有限公司 | 一种益生菌复配低聚肽降尿酸营养补充剂 |
CN105876777A (zh) * | 2016-04-12 | 2016-08-24 | 周安琪 | 具有降低尿酸作用的食品及其制备工艺 |
CN106720797A (zh) * | 2016-12-29 | 2017-05-31 | 武汉万松堂健康产业有限公司 | 一种具有降尿酸、护肝强肾功效的养生茶及其制备方法 |
CN106975028A (zh) * | 2017-02-24 | 2017-07-25 | 广西健铧健康产业有限公司 | 一种治疗痛风的中药制剂的制备方法 |
CN106901287A (zh) * | 2017-03-17 | 2017-06-30 | 济南大学 | 一种基于益生菌发酵的中药解酒护肝果冻及制备方法 |
CN107136377A (zh) * | 2017-06-21 | 2017-09-08 | 武汉万松堂健康产业有限公司 | 一种针对痛风及高尿酸人群的复合固体饮料及其制备方法 |
Non-Patent Citations (5)
Title |
---|
《健康大讲堂》编委会: "《痛风怎么吃》", 30 September 2015, 哈尔滨:黑龙江科学技术出版社 * |
A.LAUKOVA: "Adhesion properties of enterococci to intestinal mucus of different hosts", 《VETERINARY RESEARCH COMMUNICATIONS》 * |
G. C. MEAD: "Anaerobic Utilization of Uric Acid by Some Group D Streptococci", 《JOURNAL OF GENERAL MICROBIOLOGY》 * |
段永禄: "《痛风的饮食宜忌与调养》", 31 January 2013, 太原:山西科学技术出版社 * |
洪钦国 等: "《中西医结合肾脏病诊断治疗学》", 31 March 2001, 广州:广东科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111195266A (zh) * | 2019-12-20 | 2020-05-26 | 江苏微康生物科技有限公司 | 具有缓解高尿酸作用的益生菌组合物及其应用 |
CN111195266B (zh) * | 2019-12-20 | 2022-11-01 | 微康益生菌(苏州)股份有限公司 | 具有缓解高尿酸作用的益生菌组合物及其应用 |
CN111248382A (zh) * | 2020-02-28 | 2020-06-09 | 山东理工大学 | 栀子茯苓复合饮品及其制备方法 |
CN115895966A (zh) * | 2022-11-30 | 2023-04-04 | 天津小薇生物科技有限公司 | 一株辅助缓解痛风的两歧双歧杆菌bl002及其应用 |
CN115895966B (zh) * | 2022-11-30 | 2024-03-22 | 天津小薇生物科技有限公司 | 一株辅助缓解痛风的两歧双歧杆菌bl002及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102754753B (zh) | 用于改善肉仔鸡生长性能的饲料及其制备方法 | |
JP5498698B2 (ja) | シロキクラゲ雑多糖またはその抽出物の新用途 | |
CN107496850B (zh) | 一种调节肠道微生态制剂的配方及应用 | |
KR100813914B1 (ko) | 장내 생균제 공동-발효 배양물에 의한 천연 의약의 전환과변형 | |
CN103638372B (zh) | 一种中药组合物及其制备方法和应用 | |
CN110338402A (zh) | 一种复合益生菌粉及其制备方法 | |
CN107568736A (zh) | 解酒醒酒医学配方食品 | |
CN105942128A (zh) | 一种草本酵母益生菌固体饮料及其制备方法和应用 | |
CN104223074A (zh) | 便秘全营养配方食品 | |
CN109528814B (zh) | 一种乳酸菌发酵黄芪的微生态制剂及其制备方法和应用 | |
CN110313599A (zh) | 一种降尿酸果冻及其制备方法 | |
CN101336661B (zh) | 一种非特异性复合多糖免疫乳及其制备方法 | |
CN107441368A (zh) | 一种具有提高免疫力作用的药食同源组合物及其制备方法 | |
CN104187637A (zh) | 壮阳全营养配方食品 | |
CN106173450A (zh) | 提高鸽子免疫力的复方饲料添加剂及饲料 | |
CN114452308A (zh) | 一种益生菌保护剂及其制备的微生态制剂和用途 | |
CN104256656A (zh) | 脂肪酸代谢异常全营养配方食品 | |
CN105029392A (zh) | 鼻咽癌医学配方食品 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN110192653A (zh) | 一种孕产妇及儿童专用益生菌的制备方法 | |
CN105727253A (zh) | 保肝清毒预防治疗肝脏及相关代谢性疾病的组合物及制备方法 | |
CN104146267A (zh) | 红斑狼疮全营养配方食品 | |
CN104187650A (zh) | 特禀体质全营养配方食品 | |
CN103263538B (zh) | 对畜禽滋补消炎止泻止血止痛的中药组合物及制备方法 | |
CN111264865A (zh) | 一种甲状腺结节医学配方食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 510000 Room 101, 2nd floor, building B, No.2 Ruitai Road, Guangzhou high tech Industrial Development Zone, Guangzhou, Guangdong Province Applicant after: Guangzhou SuoYuan Biotechnology Co.,Ltd. Address before: 510000 Room 101, 2nd floor, building B, No.2 Ruitai Road, Guangzhou high tech Industrial Development Zone, Guangzhou, Guangdong Province Applicant before: Guangzhou Traceable Biotechnology Co.,Ltd. |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191011 |
|
RJ01 | Rejection of invention patent application after publication |